What is AD-227C used for?

AD-227C is indicated for Treatment-resistant depression.

AD-227C is developed by Addpharma Inc..

What are the side effects of AD-227C?

Common side effects include Nausea, Headache, Dizziness.

Last reviewed 2026-04-23 · How we verify

AD-227C

Addpharma Inc. · Phase 3 active Small molecule

AD-227C is a small molecule drug that targets the serotonin receptor.

AD-227C is a small molecule drug that targets the serotonin receptor. Used for Treatment-resistant depression.

At a glance

Generic name	AD-227C
Sponsor	Addpharma Inc.
Drug class	Serotonin receptor antagonist
Target	5-HT2A receptor
Modality	Small molecule
Therapeutic area	Psychiatry
Phase	Phase 3

Mechanism of action

AD-227C works by selectively binding to the serotonin receptor, which helps to modulate various physiological processes. This interaction can lead to therapeutic effects in certain conditions.

Approved indications

Treatment-resistant depression

Common side effects

Nausea
Headache
Dizziness

Key clinical trials

A Study to Evaluate the Efficacy and Safety of Co-administration of AD-227A and AD-227B (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results